Tonix Pharmaceuticals Holding (TNXP) Other financing activities (2013 - 2026)

Tonix Pharmaceuticals Holding's Other financing activities history runs 12 years deep, the most recent figure standing at $79000.0 for Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $79000.0 in Q1 2026; TTM through Mar 2026 was $83000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $27000.0, down 6.9% from the prior year.
• Other financing activities climbed to $79000.0 in Q1 2026 per TNXP's latest filing, from $4000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $79000.0 in Q1 2026 and bottomed at $4000.0 in Q3 2024.
• The 4-year median for Other financing activities is $29000.0 (2023), against an average of $35000.0.
• Across the five-year window, Other financing activities soared 42.86% in 2022 and slipped 27.5% in 2023, its largest moves.
• Year by year, Other financing activities stood at $40000.0 in 2022, then declined by 27.5% to $29000.0 in 2023, then slumped by 86.21% to $4000.0 in 2024, then soared by 1875.0% to $79000.0 in 2026.
• Per Business Quant, the three latest TNXP Other financing activities figures stand at $79000.0 (Q1 2026), $4000.0 (Q3 2024), and $23000.0 (Q1 2024).